
2022 PDA VIRUS CONFERENCE



CHANGING LANDSCAPE OF VIRAL SAFETY -EXISTING AND ADVANCED TECHNOLOGIES pda.org/EU/Virus2022

20-21 JUNE 2022 BRUSSELS, BELGIUM EXHIBITION: 20-21 JUNE

REGISTER BEFORE 24 APRIL AND SAVE UP TO €200!



WELCOME FROM THE CHAIRS

Dear Colleagues,

On behalf of the Scientific Program Planning Committee and PDA, we would be glad to see you at the Virus Conference to take place in Brussels, Belgium.

This global meeting is organized in close collaboration with an excellent Scientific Program Planning Committee including European and U.S. FDA regulators, industry experts, supplier specialists, and dedicated PDA Europe support.

The overall program is designed to provide an update on regulatory expectations and the scientific framework around the virus safety of plasma-derived and biotechnology medicinal products, as well as particularly innovative cell- and gene therapies.

Similar to earlier events in this long-standing series, current and newly emerging viral threats, viral safety considerations around the selection of low-risk starting materials, virus detection and identification methods and strategies, and the design and validation of virus inactivation and removal processes will be key topics for discussion. In addition, intensified continuous manufacturing processes and their potential impact on facility design and viral safety will also be considered.

After a sequence of online-only events, forced by the emergence of SARS- CoV-2, the PDA Virus Conference will provide attendees the unique opportunity to re-gather in person for interactive discussions and benchmarking, as well as to reinvigorate social interactions. A discussion forum that allows direct interaction between industry and regulators will continue to support the wider industry and improve the current understanding and acceptance of new technologies, highlight new and emerging viral risks, and explain novel regulatory approaches.

Panel discussions and ample networking opportunities will complement an impressive scientific program and make it a worthwhile and well-rounded experience for you.

We look forward to seeing you!

Sincerely, The Chairs



Alison Armstrong, Merck KGaA



Thomas R. Kreil, *Takeda*

SCIENTIFIC PROGRAM PLANNING COMMITTEE

Alison Armstrong, Merck KGaA, Chair Thomas R. Kreil, Takeda, Chair Andy Bailey, ViruSure Johannes Blümel, Paul-Ehrlich-Institut Qi Chen, Genentech/Roche Arifa S. Khan, U.S. FDA Sean O'Donnell, Eli Lilly & Company Mehran Rafigh, Sartorius Stedim Sebastian Teitz, Asahi Kasei Josh Eaton, PDA Falk Klar, PDA Stefanie Nebelin, PDA Manager Programs & Events

WELCOME TO VIRUS CONFERENCE

COVID-19 PERSONAL PRECAUTIONARY MEASURES PDA is committed to deliver safe and secure in-person events. In conjunction with the venue and vendors supporting our event, PDA strictly adheres to all national, provincial and local government regulations.

CONFERENCE AGENDA

MONDA	Y, 20 JUNE 2022	09:00 - 17:30
09:00	Welcome and Introduction	Falk Klar, PDA Europe
	Welcome from the Chairs	Alison Armstrong, <i>Merck KGaA</i> Thomas R. Kreil, <i>Takeda</i>
	Keynote: New Methods to Ensure Virus Safety in the Production of Biologics	Norcliffe Partners
OPENING	G PLENARY: Updates from the Regulatory Landscape	Moderators: Alison Armstrong, Merck KGaA Thomas R. Kreil, Takeda
manufact considera address u approach	dvances in biomanufacturing practices have supported the accelerated growth ured using cell lines of human and animal origin continue to be at risk of viral cont tion. With recent advances in science and manufacturing systems, ICHQ5A (R2) updated detection technologies and advise on manufacturing paradigms and r es to mitigate risk are a regulatory expectation, and real-world data on viral cleara n of state-of-the-art biotechnology manufacturing processes.	amination, and thus biosafety strategies are a key is undergoing revision to include novel therapies nodified viral clearance applications. Orthogona
	Update on the revision of Guideline ICHQ5A	Johannes Blümel, PEI
	Regulatory Update of Viral Safety	U.S. FDA
	Q&A, Discussion	
11:05	COFFEE BREAK, POSTER SESSION & EXHIBITION	
SESSION	1: Virus Filtration	Moderator: Sean O'Donnell, Eli Lilly
removal o	ation is a very robust method for the removal of a broad host range of viruses so f the virus through viral filtration, which includes volumetric throughput, start, st of virus load on virus breakthrough and the effects of filter fouling on virus break	op of flow, and pressure. This session will discuss
	Visualizing Protein Fouling and its Impact on Parvovirus Retention Within Distinct Filter Membrane Morphologies	CSL Behring
	A New Reliable Approach to Viral Clearance Study Design from the Amount of Virus Load	Asahi-Kasei
	Q&A, Discussion	
12:55	LUNCH BREAK, POSTER SESSION & EXHIBITION	
SESSION	2: Preparedness of Biotechnology Industry against Pandemics	Moderator: Johannes Blümel, PEI
the COVIE	lemics pose a threat, not only to the viral safety of biological products but also to 0-19 pandemic on supply issues will be explained. Beyond coronaviruses, the pot consequences to humans and biomedical products will be discussed.	
	Zoonotic Viruses and Humans: Emerging, Pandemic, and Seasonal Patterns of Circulation	Thomas R. Kreil, <i>Takeda</i>
	Dual Sourcing of Raw Materials during the Pandemic	Genentech/Roche
	Q&A, Discussion	
15:15	COFFEE BREAK, POSTER SESSION & EXHIBITION	

CONFERENCE AGENDA

SESSION	I 3: Next Generation Sequencing and Virus Detection	Moderator: Jean-Pol Cassart, GSK
menting c	bilities of NGS for the detection of known and novel viruses have advanced the use or replacing the currently used in vivo and in vitro adventitious virus detection assays virus detection in biological materials and virus discovery in support of NGS use for l	s. This session will present studies demonstrat
	Identification of an EHDV Contamination Event in a	Andy Bailey,
	Biopharmaceutical Product Using a Combination of Adventitious Agent Testing and Next Generation Sequencing	ViruSure
	Use of Next Generation Sequencing Technology for Broad Virus Screening in Biologically Derived Samples: A Case Study with SARS-CoV-2 Challenge Virus	Merck KGaA
	NGS Contribution to Virus Discovery: Bat Coronaviruses related to SARS-CoV-2 and Infectious for Human Cells	Institut Pasteur
	Q&A, Discussion	
17:30	END OF CONFERENCE DAY 1 & NETWORKING EVENT	



CONFERENCE AGENDA

TUESDAY	7, 21 JUNE 2022	08:00 - 16:30		
08:00	INTEREST GROUP MORNING SESSION: Advanced Virus Detection Technologies IG (AVDTIG) Session	Moderator: Arifa Khan, U.S. FDA		
qualificatior achievemer	B is a multidisciplinary international effort with a focus on developing standa of NGS technologies for adventitious virus detection in biologics. The session its of the IG, and the status of ongoing collaborative studies for evaluating virus s. The session will close with audience Q&A and discussion.	n will provide background, ongoing activities, and		
	Updates on NGS Activities and Achievements in AVDTIG	GSK		
	Q&A, Discussion			
SESSION 4	: Virus Inactivation	Moderator: Andy Bailey, ViruSure		
Virus inactivation has and continues to play an important role in ensuring the virus safety of biological products. The mechanisms of inacti- vation and conditions for ensuring robust inactivation via detergent or low pH are well understood, but new challenges arising from a reduced dependency on the detergent Triton X-100 or with the implementation of low pH in a continuous manufacturing environment require new approaches. This session will provide a discussion forum for how these challenges can be met using actual case studies.				
	Detergent-based Virus Inactivation: Development and Evaluation of an Alternative for Triton X-100	Takeda		
	Identification of an Environmentally friendly Detergent as a Replacement for Triton X-100 in Virus Inactivation	Sean O'Donnell, Eli Lilly		
	Transitioning Low pH Mediated Viral Inactivation in Bioprocessing from Batch to Continuous Mode	MillporeSigma		
	Q&A, Discussion			
10:30	COFFEE BREAK, POSTER SESSION & EXHIBITION			
SESSION 5	: Viral Clearance	Moderator: Sebastian Teitz, Asahi Kasei		
by far the la edge for im	oncept that is commonly referred to as the "Virus Safety Tripod of Biopharmac rgest proportion in risk reduction to the biopharmaceutical product. This sessi proved & successful virus validation programs, simplified & more efficient HEV c of low pH inactivation.	on will explore the systematic use of prior knowl-		
	A Database for Virus Clearance Data for Improved Virus Validation Programs	Genentech		
	Efficient HEV Production in Tissue Culture and its Application in Inactivation studies	Ruhr Uni Bochum		
	Characterizing a Novel Parameter Affecting Low pH Viral Inactivation	Regeneron		
	Q&A, Discussion			
12:40	LUNCH BREAK, POSTER SESSION & EXHIBITION			
CLOSING F	PLENARY: Industry Forums	Moderators: Alison Armstrong, Merck KGaA Thomas R. Kreil, Takeda		
Patient safe	ty is a shared priority for the biopharmaceutical industry as well as regulatory b	odies. To ensure adequate virus safety margins of		

Patient safety is a shared priority for the biopharmaceutical industry as well as regulatory bodies. To ensure adequate virus safety margins of medicinal products, collaboration rather than competition is often chosen by the parties involved, to make most effective use of the totality of available data and experiences. Two notable collaborative studies and their results will be presented and discussed.

CONFERENCE AGENDA / INFORMATION

	Interactive Questionnaire	
	Update on PDA's Technical Report #41 on Virus Filtration	Invited Speaker
14:05	Coffee Break, Poster Session & Exhibition	
	MIT CAACB Risk Assessment Case Study: Assessing Virus Cross-Contamination Risk between Two Simultaneous Processes in an Open Biomanufacturing Facility	Massachusetts Institute of Technology
	Panel Discussion	<i>Moderators:</i> Alison Armstrong, <i>Merck KGaA</i> Thomas R. Kreil, <i>Takeda</i>
	Summary by the Chairs	Alison Armstrong, <i>Merck KGaA</i> Thomas R. Kreil, <i>Takeda</i>
	Closing Remarks & Farewell	Falk Klar, PDA Europe
16:15	END OF CONFERENCE	

The agenda is subject to change without notice

VENUE

TANGLA HOTEL BRUSSELS

Avenue Emmanuel Mounier 51200 Brussels/Belgium Tel: +32 2775 2508 tanglabrussels.com/en/

GENERAL ADDRESS

PDA Europe gGmbH Am Borsigturm 60 13507 Berlin, Germany T: + 49 30 436 55 08-0 F: + 49 30 436 55 08-66 info@pda.org

SPECIAL REQUIREMENTS

If you require special assistance to fully participate, please attach a written description of your needs with your registration form. Specific questions can be directed to info@pda.org.



PDA EUROPE UPCOMING CONFERENCES AND EVENTS

FOR FURTHER INFORMATION FOLLOW US ONLINE

www.pda.org

2022	05. Apr 2022	
26-27 APR 2022	2022 PDA Visual Inspection Forum	Berlin, Germany
16-17 MAY 2022	2022 PDA Medical Devices and Connected Health Conference	Dublin, Ireland
16-17 MAY 2022	2022 PDA Robotics and Automation Conference	Dublin, Ireland
18-19 MAY 2022	2022 PDA Annex 1 Workshop	Dublin, Ireland
02-03 JUN 2022	2022 PDA Parenteral Packaging Conference	Basel, Switzerland
20-21 JUN 2022	2022 PDA Virus Conference	Brussels, Belgium
22-23 JUN 2022	2022 PDA Advanced Therapy Medicinal Products Conference	Brussels, Belgium
20-21 SEP 2022	2022 PDA BioManufacturing Conference	Amsterdam, The Netherlands
22-23 SEP 2022	2022 PDA Annex 1 Workshop	Amsterdam, The Netherlands
05-06 OCT 2022	2022 PDA Quality and Regulations Conference	Amsterdam, The Netherlands